Cancer Research

Cancer Research
  • Pininvest Analysis

Our selection for cancer research attempts to mirror some of the transformative forces at play in biotechnology

Clinical stage research remains a significant market segment as large pharmaceutical enterprises see value in farming out some of their research – read our theme dedicated to clinical companies (to be published soon)

But, conversely, large biopharma companies, often highly valued by the market because of their growth expectations, may consider integration of former or current partner firms to diversify their drug pipeline – possibly guaranteeing a significant part of future earnings of future drugs to former owners, to clinch a deal …

Read our note

Cancer Research • Updated:

Name Ticker Exchange Sector Industry Currency Cur.Price Mkt.Cap Perf. Momentum Vol. Risk Contrib. MDD
 
bluebird bio, Inc. BLUE NASDAQ Health Care Biopharmaceuticals USD 29.34 1.9 B -59.8% Sharp Down 81%   10% -65%
Bristol-Myers Squibb BMY NYSE Health Care Drug Manufacturers - Diversified USD 60.75 137 B 1.8% Neutral 29%   3% -25%
Geron GERN NASDAQ Health Care Drug Manufacturers - Diversified USD 1.70 528 M 47.8% Neutral 70%   9% -29%
Incyte Corporation INCY NASDAQ Health Care Drug Manufacturers -Specialty Pharma USD 76.02 17 B -5.2% Weak Down 43%   5% -31%
Inovio Pharmaceuticals INO NASDAQ Health Care Biopharmaceuticals USD 9.56 1.6 B 19.1% Weak Down 165%   17% -73%
Lumos Pharma LUMO NASDAQ Health Care Biopharmaceuticals USD 14.27 118 M 3.6% Sharp Down 83%   8% -62%
Merrimack Pharmaceuticals, Inc. MACK NASDAQ Health Care Biopharmaceuticals USD 6.92 93 M 117.6% Neutral 82%   6% -26%
NantKwest, Inc. NK NASDAQ Health Care Biopharmaceuticals USD 26.58 2.9 B 389.5% Strong Up 132%   19% -37%
Seattle Genetics Inc. SGEN NASDAQ Health Care Biopharmaceuticals USD 147.93 27 B 27.5% Weak Down 50%   7% -30%
Siemens Healthineers SMMNY OTC Health Care Medical Devices USD 27.62 - 30.7% Neutral 35%   3% -20%
ZIOPHARM Oncology ZIOP NASDAQ Health Care Biopharmaceuticals USD 4.68 1.0 B 48.1% Strong Up 88%   13% -44%